Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, everyone, and welcome to the ATF Pharmaceuticals 3rd Quarter 2025 Financial Results and Business Update Conference Call. At this time, all participants are in listen-only mode. Following the formal remarks, we'll open the call up for your questions. I would now like to turn the call over to Jonay Barnes, Senior Vice President of Investor Relations and Corporate Communication at ATF Pharmaceuticals. Ms. Barnes, please proceed. Thank you, Operator. Good afternoon, everyone, and welcome to Atea Pharmaceutical's third quarter 2025 financial results and business update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at ir.ateafarma.com. With me from Atea are our Chief Executive Officer and Founder, Dr. John-Pierre Sommadosi, Chief Development Officer, Dr. Janet Hammond, Chief Medical Officer, Dr. Arantja Horga, Chief Commercial Officer, John Vavrica, and Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran, all of whom will be available for the Q&A portion of today's call. Before we begin the call, and as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre. Thank you, Janae. Good afternoon, everyone, and thank you for joining us. I will b...